Firms link on cardiovascular disease and diabetes
This article was originally published in Clinica
Executive Summary
Cholestech and Bayer Diagnostics are forming a co-marketing deal to cover diagnosis and management of cardiovascular disease and diabetes. The "risk management programme" will offer more than 100,000 physician office laboratories and acute care facilities access to the Cholestech LDX lipid management system and Bayer's DCA 2000 analyser for diabetes management.